DCC St. Vrach and St. St. Kuzma and Damian
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dimitrova, Petya
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Terminated
3
83
Europe, Canada, Japan, US
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.
Depressive Episodes, Bipolar I Depression
10/23
10/23
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Recruiting
2/3
434
Europe, Japan, US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
02/25
02/25
Kotetarov, Vasil
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Terminated
3
83
Europe, Canada, Japan, US
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.
Depressive Episodes, Bipolar I Depression
10/23
10/23
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Recruiting
2/3
434
Europe, Japan, US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
02/25
02/25
Popov, Nikolay
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting
3
150
Europe, Canada, US, RoW
Ecopipam, Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Syndrome
11/24
03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Recruiting
3
196
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
12/24
12/24
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Recruiting
2/3
434
Europe, Japan, US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
02/25
02/25

Download Options